Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aprea Therapeutics ( (APRE) ) has issued an announcement.
On August 12, 2025, Aprea Therapeutics reported its financial results for the second quarter ending June 30, 2025, and provided a clinical update. The company observed early evidence of disease control in its ongoing Phase 1 ACESOT-1051 trial with the WEE1 inhibitor, APR-1051, and its ATR inhibitor, ATRN-119, showing early activity in a dose escalation study. The company reported a net loss of $3.2 million for the quarter, with cash and cash equivalents of $16.5 million, expected to support operations into Q2 2026. Aprea’s collaboration with MD Anderson Cancer Center has shown promising preclinical results, positioning APR-1051 for potential combination-based clinical trials.
The most recent analyst rating on (APRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.
Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells. The company’s lead programs include APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, both targeting solid tumor indications.
Average Trading Volume: 51,964
Technical Sentiment Signal: Sell
Current Market Cap: $9.35M
Learn more about APRE stock on TipRanks’ Stock Analysis page.